Document Detail


Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
MedLine Citation:
PMID:  23211287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome in which affected individuals are predisposed to the development of multiple leiomyomas of the skin and uterus and aggressive forms of kidney cancer. Affected individuals harbor a germline heterozygous loss-of-function mutation of the fumarate hydratase (FH) gene. Uterine leiomyomas are present in up to 77% of women with this syndrome. Previous studies have shown that inactivation of the FH gene is unusual for nonsyndromic leiomyomas. Therefore, it might be possible to distinguish 2 genetic groups of smooth muscle tumors: the most common group of sporadic uterine leiomyomas without FH gene inactivation and the more unusual group of HLRCC leiomyomas in patients who harbor a germline mutation of FH, although the exact prevalence of hereditary HLRCC is unknown. We reviewed the clinical, morphologic, and genotypic features of uterine leiomyomas in 19 HLRCC patients with FH germline mutations. Patients with HLRCC syndrome were younger in age compared with those with regular leiomyomata. DNA was extracted by microdissection, and analysis of loss of heterozygosity (LOH) at 1q43 was performed. Uterine leiomyomas in HLRCC have young age of onset and are multiple, with size ranging from 1 to 8 cm. Histopathologically, HLRCC leiomyomas frequently had increased cellularity, multinucleated cells, and atypia. All cases showed tumor nuclei with large orangeophilic nucleoli surrounded by a perinucleolar halo similar to the changes found in HLRCC. Occasional mitoses were found in 3 cases; however, the tumors did not fulfill the criteria for malignancy. Our study also showed that LOH at 1q43 was frequent in HLRCC leiomyomas (8/10 cases), similarly to what has been previously found in renal cell carcinomas from HLRCC patients. LOH is considered to be the second hit that inactivates the FH gene. We conclude that uterine leiomyomas associated with HLRCC syndrome have characteristic morphologic features. Both, uterine leiomyomas and renal cell carcinoma share some morphologic nuclear changes and genotypic features in HLRCC patients. The specific morphologic features of the uterine leiomyomas that we describe may help in the identification of patients who may be part of the hereditary syndrome.
Authors:
Julian Sanz-Ortega; Cathy Vocke; Pamela Stratton; William Marston Linehan; Maria J Merino
Related Documents :
25216697 - Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome ...
22239847 - Treatment of ascites and spontaneous bacterial peritonitis - part i.
23560847 - Unspecific increase of tumor markers in a girl with nephrotic syndrome and ovarian tera...
24024657 - Secondary amenorrhea in severe asherman's syndrome: step by step fertility retrieval by...
25216697 - Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome ...
10063207 - Clinical and immunological characterization of patients with systemic sclerosis overlap...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of surgical pathology     Volume:  37     ISSN:  1532-0979     ISO Abbreviation:  Am. J. Surg. Pathol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-17     Completed Date:  2013-02-12     Revised Date:  2014-01-10    
Medline Journal Info:
Nlm Unique ID:  7707904     Medline TA:  Am J Surg Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  74-80     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Carcinoma, Renal Cell / genetics,  pathology*
Cell Nucleus / pathology
DNA, Neoplasm / genetics
Female
Fumarate Hydratase / genetics*
Germ-Line Mutation*
Humans
Kidney Neoplasms / genetics,  pathology*
Leiomyoma / genetics,  pathology*
Leiomyomatosis / genetics,  pathology*
Loss of Heterozygosity
Middle Aged
Neoplastic Syndromes, Hereditary / genetics,  pathology*
Skin Neoplasms
Syndrome
Tumor Markers, Biological / genetics
Uterine Neoplasms / genetics,  pathology*
Young Adult
Grant Support
ID/Acronym/Agency:
Z01 BC010696-03/BC/NCI NIH HHS
Chemical
Reg. No./Substance:
0/DNA, Neoplasm; 0/Tumor Markers, Biological; EC 4.2.1.2/Fumarate Hydratase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection.
Next Document:  Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyp...